Company Directory - Absci Corporation
Company Details - Absci Corporation
Absci Corporation
WebsiteAbsci is a generative AI drug discovery company that combines artificial intelligence with biological data.
CCI Score
CCI Score: Absci Corporation
19.24
-0.08%
Latest Event
Strategic Partnership for AI-Driven Drug Discovery
Absci Corporation and Owkin announced a strategic partnership on January 10, 2025, to combine their advanced AI platforms for accelerating the discovery and development of novel therapeutics in areas such as immuno-oncology and immunology. The collaboration aims to integrate Absci’s generative AI drug creation capabilities with Owkin’s predictive target discovery technology to streamline the transition from research to clinical development.
Take Action
So what can you do? Support Absci by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
SABOTEUR
Absci Corporation is currently rated as a Saboteur.
Latest Events
- JAN102025
Absci Corporation and Owkin announced a strategic partnership on January 10, 2025, to combine their advanced AI platforms for accelerating the discovery and development of novel therapeutics in areas such as immuno-oncology and immunology. The collaboration aims to integrate Absci’s generative AI drug creation capabilities with Owkin’s predictive target discovery technology to streamline the transition from research to clinical development.
+60
Business Practices and Ethical Responsibility
March 28
The partnership demonstrates strong ethical business practices by forging collaborations that enhance drug discovery and improve public health outcomes. By joining forces with an industry leader, Absci reinforces its commitment to innovation and responsible growth in the biotech sector.
+70
Technology and Services Impact
March 28
The collaboration leverages cutting‐edge AI platforms to boost the pace of drug design and discovery, representing a significant positive impact in technology and services. This innovative use of AI has the potential to transform therapeutic development and deliver benefits to public health.
+50
Economic and Structural Influence
March 28
By forming a strategic alliance with Owkin, Absci is not only advancing its own technological capabilities but also contributing to a broader structural innovation within the biotech sector. This enhances the company's market position and supports sustainable industry progress.
- DEC312023
According to data from OpenSecrets, Absci Corporation spent $30,000 on lobbying efforts during the 2023 cycle, indicating the company’s engagement in influencing federal policy.
-30
Political Contributions and Lobbying Efforts
March 28
Absci Corporation’s spending of $30,000 on lobbying in 2023 raises concerns regarding corporate attempts to influence political processes. Such lobbying activities can contribute to regulatory capture and bolster corporate interests over public welfare, which is counterproductive to anti-fascist values and worker protections.
- DEC042023
Absci has entered a $247 million collaboration with AstraZeneca to use its generative AI technology to design and optimize new antibody treatments for cancer. Under the deal, Absci will generate potential synthetic antibodies while AstraZeneca will handle research and development costs, with Absci receiving royalty fees if the drug is successful.
+70
Technology and Services Impact
March 28
Absci's innovative use of generative AI in partnership with AstraZeneca to develop potentially life-saving cancer treatments demonstrates a forward-thinking and socially beneficial application of technology. This approach not only advances drug development but also supports public health, aligning with progressive values and resisting any authoritarian misuse of technology.
AstraZeneca and Absci Join Forces to Develop AI-Generated Cancer Treatments in $247 Million Deal
- JAN012023
OpenSecrets reports that Absci Corporation spent $30,000 on lobbying activities in 2023, highlighting its engagement in political processes.
-20
Political Contributions and Lobbying Efforts
March 28
Absci Corporation's reported spending of $30,000 on lobbying in 2023 reflects an engagement in political influence. While lobbying is a common corporate practice, from an anti-fascist perspective such activities can be seen as attempts to shape policy in favor of corporate interests over democratic accountability, raising concerns about undue influence and potential support for oligarchic power structures.
Alternatives
Corporation
0.00
Canada
48.75
Somerset, United States
1.17
San Diego, United States
0.00
USA
0.00
San Carlos, United States
-24.65
San Diego, United States
-29.93
Indianapolis, United States
-34.93
Cambridge, USA
-42.53
Menlo Park, United States
-49.21
Industries
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 541711
- Research and Development in Biotechnology